A61K 40/30
Cellular immunotherapy: characterised by the recombinant expression of specific molecules in the
Official title: characterised by the recombinant expression of specific molecules in the cells of the immune system
A61K40/30 (Cellular immunotherapy: characterised by the recombinant expression of specific molecules in the) appears on 2,746 US grants and 7,799 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,746
- Published applications
- 7,799
- Assignees
- 1,840
- Inventors
- 10,911
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 3 |
| 2002 | 2 | 26 |
| 2003 | 4 | 23 |
| 2004 | 9 | 25 |
| 2005 | 2 | 7 |
| 2006 | 7 | 21 |
| 2007 | 2 | 16 |
| 2008 | 13 | 25 |
| 2009 | 6 | 35 |
| 2010 | 18 | 26 |
| 2011 | 14 | 43 |
| 2012 | 15 | 25 |
| 2013 | 23 | 42 |
| 2014 | 19 | 72 |
| 2015 | 27 | 60 |
| 2016 | 50 | 119 |
| 2017 | 50 | 203 |
| 2018 | 74 | 312 |
| 2019 | 110 | 471 |
| 2020 | 226 | 631 |
| 2021 | 239 | 806 |
| 2022 | 291 | 905 |
| 2023 | 310 | 922 |
| 2024 | 391 | 1130 |
| 2025 | 468 | 1016 |
| 2026 | 370 | 835 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases8 Oct 2026US 2026/0306629 A1
- Chimeric receptors8 Oct 2026US 2026/0306631 A1St. Jude Children?S Research Hospital
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies343US 6,410,319 B1City of Hope · 2002
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Chimeric receptor genes and cells transformed therewith327US 7,741,465 B12010
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014